Background
==========

Rising healthcare costs, limited resources, and the aging population have created new and growing challenges in the management of osteoarthritis (OA). The challenges associated with the management of OA are numerous as the prevalence of the population continues to increase while healthcare resources remain limited \[[@B1]-[@B7]\]. It is therefore necessary to determine the most effective methods of integrating research evidence in order to optimize health outcomes.

The purpose of this randomized controlled trial (RCT) was to compare 1) improvements in quality of life (QoL) and clinical outcomes such as pain, mobility and endurance); 2) adherence rates; and 3) confidence and self-efficacy after the implementation of a 12-month supervised community-based aerobic walking program (SCAWP) based on the Ottawa Panel clinical practice guidelines (CPG) among three knowledge translation (KT) intervention arms. QoL, confidence, and self-efficacy were compared at 12- months (end of treatment) and at 18-months (6-months post-intervention). Adherence was compared during the intervention period at 3, 6, 9 and 12 months.

The first part of this manuscript introduces each KT intervention and demonstrates the impact of knowledge (CPG) uptake of each by comparing outcomes influenced by the KT intervention such as adherene and behaviour change (confidence and self-efficacy). Knowledge application of each KT intervention is explained through the use a theoretical framework: Knowledge-To-Action Cycle (KTAC) \[[@B8],[@B9]\]. The second part of this manuscript focuses on outcome evaluation, a specific phase in the KTAC framework used to guide this study. Part II demonstrates the effect of each intervention involving a walking program on outcomes which were influenced by the SCAWP including QoL (primary outcome) and other clinical outcomes such as pain, mobility, and endurance. These outcomes are exhibited in part II. Therefore, both parts of this manuscript were split according to the ''Evaluate outcomes" phase of the KTAC framework. Part I focused on KT outcomes which measured the success of CPG uptake through participants' adherence and behavioural change while part II focused on clinical outcomes which measured the positive effect of SCAWP due to the indirect CPG uptake/implementation/adoption by individuals with OA of the knee.

Knowledge translation
---------------------

A major issue in health research today is finding effective and efficient ways to exchange knowledge between researchers, clinicians and the general public. Potential benefits to health which could be accrued through the application of research findings are not realized due to challenges in research uptake and knowledge translation \[[@B10]\]. KT is defined by Estabrooks et al. \[[@B11]\] as *"the process by which specific research-based knowledge (science) is implemented in practice."*

The available evidence suggests that with an effective KT strategy, uptake of evidence-based clinical practice guidelines (EBCPGs) can be effective in improving patient health outcomes \[[@B12]\].

Physical activity and osteoarthritis
------------------------------------

The promotion of physical activity (PA) is a priority for health organizations serving the general population \[[@B13],[@B14]\] and is highly recommended for subgroups affected by chronic diseases \[[@B15]-[@B19]\]. Community-based PA combined with a behavioural modification and self-management interventions can reduce the risk of disability and negative consequences of inactivity related to OA \[[@B20],[@B21]\]. The challenge is to develop PA programs that will encourage OA patients to initiate and maintain improvements in exercise behaviour over a long-term period \[[@B22]\]. The available evidence suggests that with an effective KT strategy, uptake of evidence-based clinical practice guidelines (CPGs) can be effective in improving patient health outcomes \[[@B12]\].

Selecting an effective KT strategy
----------------------------------

Multifaceted interventions combining more than one KT strategy have tended to be more effective than using a single KT strategy alone \[[@B23],[@B24]\] and have shown to have the greatest impact on CPG adherence and PA performance \[[@B25]\]. Behavioural interventions have been used for other chronic conditions to improve long-term adherence and maintenance of PA regimens with varying success. The efficacy of different behavioural interventions including patient education, health counselling, goal setting, and social/peer support, delivered separately and or in combination, have been examined in the management of arthritis \[[@B26]-[@B31]\].

Methods
=======

The following methodology is in full agreement with the Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement criteria for reporting RCTs \[[@B32]\].

Design
------

This single blind RCT, funded by the Canadian institutes of Health Research, used a parallel group design (1:1:1). This community-based study was approved by the University of Ottawa Research Ethics Board and the City of Ottawa Public Health Research Ethics Board. This study implemented one of the Ottawa Panel CPG recommendations related to a supervised community-based aerobic walking programs (SCAWPs) among individuals with mild to moderate OA of the knee \[[@B33]-[@B35]\].

In order to facilitate an understanding of the KT process, Graham et al. developed a conceptual framework entitled "the Knowledge-To-Action Cycle" (Figure  [1](#F1){ref-type="fig"}) which provides an approach which combines commonalities from various planned-action theories \[[@B8],[@B9]\]. This framework was used to guide the development of the three KT strategies used in this RCT (Additional file [1](#S1){ref-type="supplementary-material"}). The framework demonstrates the dynamic process of knowledge creation and application \[[@B9]\]. Knowledge creation consists of three phases: knowledge inquiry, knowledge synthesis, and knowledge tools/products. The knowledge creation cycle of the framework demonstrates how knowledge is refined through each phase to provide useful information for end users. The action cycle of the framework consists of seven phases which may occur sequentially or simultaneously: 1) Identify the Knowledge-To-Action Cycle gaps; 2) Adapt Knowledge to local context; 3) Assess barriers to Knowledge Use; 4) Select, Tailor, Implement Interventions; 5) Monitor Knowledge Use; 6) Evaluate outcomes; and 7) Sustained Knowledge Use. For part I, the emphasis was placed on the "Evaluate outcomes (KT outcomes)" phase as participants' knowledge uptake was measured as adherence to the effective walking program for OA and attitude/behaviour change (self-efficacy and confidence) after participating in the SCAWP.

![**Knowledge-To-Action Cycle.** This figure illustrates the Knowledge-To-Action Cycle Framework \[[@B8]\]. This figure is used with permission: Lost in knowledge translation: Time for a map. Graham ID, et al. *Journal of Continuing Education in the Health Professions, 26*(1). Copyright © 2006. The Alliance for Continuing Medical Education, The Society for Academic Continuing Medical Education, and The Association for Hospital Medical Education.](1471-2458-12-871-1){#F1}

The hypothesis was that the additional behavioural approach of the multifaceted KT intervention would: 1) increase short and long term adherence to the SCAWP; 2) reduce the drop-out rate; 3) influence behaviour change by improving self-efficacy, confidence, QoL and other clinical outcomes.

Sample and recruitment
----------------------

A total of 222 adults with knee OA were recruited. Participants were eligible to participate in the study if he/she 1) had a confirmed diagnosis with mild to moderate unilateral or bilateral OA according to the American College of Rheumatology clinical and radiographic/magnetic resonance imagery criteria; 2) reported pain for at least 3 months; 3) expected his/her medication to change during the study period; 4) demonstrated an ability to ambulate for a minimum of 20 minutes, at their own pace with minimal reports of pain (≤ 3 out of 10 on a visual analogue pain rating scale) \[[@B36]\]; 4) were able to be treated as an out-patient; and 5) were available three times a week over a period of 12 months. Potential study subjects were excluded if they had: 1) Participated in regular physical or aerobic sports ≥ 2 times per week for more than 20 minutes per session during the previous 6 months; 2) severe OA of the knee or other weight bearing joints of the lower extremity; 3) no written consent from their physician to participate in the study; 4) pain at rest or at night; 5) received rehabilitation treatment, corticosteroids injection, or any other pain-related treatment besides medication for arthritis within the last 12 months; 6) uncontrolled hypertension (Systolic blood pressure \>160 mm Hg confirmed by the screening initial VO2 max test at the Ottawa Heart Institute) 7) other illnesses, such as rheumatoid arthritis (judged by the patient or study physician to make participation in this study inadvisable); 8) significant cognitive deficit resulting in an inability to understand or comply with instructions; 9) surgery planned in the next year; 10) Intention to move away from Ottawa region in the next year; 11) an inability to communicate in English or French; or 12) an unwillingness to sign informed consent. The study coordinator assessed the inclusion/exclusion criteria of all potential participants by telephone. At the first visit, written informed consent was obtained if the patient met all inclusion criteria.

Intervention
------------

Participants were randomly assigned to one of the three KT intervention groups using central randomization \[[@B37]\] and computer generated numbers \[[@B38]\]: 1) Walking and Behavioural intervention (WB) (18 males, 57 females) which included the SCAWP with a behavioural intervention and an educational pamphlet on the benefits of walking for OA; 2) Walking intervention (W) (24 males, 57 females) wherein participants only received the SCAWP intervention and the educational pamphlet; 3) Self-directed control (C) (32 males, 52 females) wherein participants only received the educational pamphlet. All 3 groups were provided with pedometers and log books to be completed to measure physical performance (walking in minutes) and additional PA aside from the walking sessions (Table [1](#T1){ref-type="table"}). The KT strategies were implemented over a 12-month duration and participants were assessed for additional 6 months (15 and 18-month follow-up assessments).

###### 

Summary of the KT strategies used

  **KT strategies in each group**                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  WB or WalkingClub+ (supervised walking program + behavioural approach at the community-based Walking Club)          W or WalkingClub (supervised walking program only at the community-based Walking Club)             C or Self-directed Home-based or community based different than W and WB (unsupervised/self-directed Walking program only)
  EBP walking program (Ottawa Panel, 2005/2012) refs: \[[@B33]-[@B35]\]                                               EBP walking program (Ottawa Panel, 2005/2012) refs: \[[@B33]-[@B35]\]                              Walking program (general info from pamphlet on walking and OA)
  Walking Club + effect (supervised program, team, daily monitored vital measures: BP, HR, \#steps,)                  Walking Club effect (supervised program, team, daily monitored vital measures: BP, HR, \#steps,)   N/A
  Pedometer as measurement tool, but becomes a KT strategy                                                            Pedometer as measurement tool, but becomes a KT strategy                                           Pedometer as measurement tool, but becomes a KT strategy
  Log book including 7-day PAR as measurement tool, but becomes a KT strategy                                         Log book including 7-day PAR as measurement tool, but becomes a KT strategy                        Log book including 7-day PAR as measurement tool, but becomes a KT strategy
  \$ compensation each walking session and at evaluation session                                                      \$ compensation each walking session and at evaluation session                                     \$ compensation each logbook fulfilled and at evaluation session
  Study affiliation/participation (feel committed)                                                                    Study affiliation/participation (feel committed)                                                   Study affiliation/participation (feel committed)
  Behavioural intervention (Baycrest PACE-ex: patient education + goal settings; PA counselling, telephone support)   N/A                                                                                                N/A

Following the successful randomization process, wherein no statistical difference was found between the three groups (with the exception of the "physical role" category of the SF-36: part II) (Tables  [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}), research staff and evaluators were blinded to the treatment allocation. An independent evaluator was blinded to assess outcome measures. Due to the nature of the physical intervention, it was not practical to blind the study participants and PA specialists supervising the aerobic walking program \[[@B39]\].

###### 

Subject demographics and baseline characteristics

  **Characteristic**                   **Walking (n=79)**    **Walking and Behavioural (n=69)**   **Self-directed Control (n=74)**        **Total**
  ----------------------------------- --------------------- ------------------------------------ ---------------------------------- ----------------------
  **Mean age (SD), yrs**                   63.9 (10.3)                   63.9 (8.2)                          62.3(6.8)                    63.4 (8.6)
  *Missing Data*                               *0*                          *0*                                 *0*                          *0*
  **Men/women, (%)**                   24 (30.4)/55 (69.9)          18 (26.1)/51 (73.9)                 27 (36.5)/47 (63.5)          69 (31.1)/153 (68.9)
  *Missing Data*                               *0*                          *0*                                 *0*                          *0*
  **Affected knee, n (%)**                                                                                                                     
  Right                                     33 (41.8)                    31 (44.9)                           25 (33.8)                    89 (40.1)
  Left                                      31(39.2)                     23 (33.3)                           28 (37.8)                    82 (36.9)
  Both side                                 15 (19.0)                    15 (28.4)                           21 (28.4)                    51 (23.0)
  *Missing Data*                               *0*                          *0*                                 *0*                          *0*
  **Mean duration of OA (SD), yrs**        9.54 (8.09)                   11.3 (9.7)                          10.0 (9.9)                  10.3 (9.26)
  *Missing Data*                               *0*                          *0*                                 *0*                          *0*
  **Mean weight (SD), kg**                 80.7 (18.5)                  83.1 (15.4)                          83.0(15.8)                  82.2 (16.6)
  *Missing Data*                               *0*                          *1*                                 *0*                          *0*
  **Mean BMI (SD), kg/m²**                 29.4 (5.4)                    30.3 (5.6)                          29.9(5.3)                    29.8 (5.4)
  *Missing Data*                               *0*                          *2*                                 *4*                          *6*
  **Walking aid, n (%)**                                                                                                                       
  Yes                                       10 (12.7)                    10 (14.5)                            9 (12.2)                    29 (13.1)
  No                                        69 (87.3)                    58 (84.1)                           64 (86.5)                    191 (86.0)
  *Missing Data*                               *0*                          *1*                                 *1*                          *2*
  **Racial background, n (%)**                                                                                                                 
  White                                     69 (87.3)                    60 (87.0)                           68 (91.9)                    197 (88.7)
  Black                                      1 (1.3)                      3 (4.3)                             1 (1.4)                      5 (2.3)
  Hispanic                                   2 (2.5)                      2 (2.9)                             4 (5.4)                      8 (3.6)
  Asian or Pacific Islander                  5 (6.3)                      4 (5.8)                             1 (1.4)                      10 (4.5)
  American Indian or Alaskan native          1 (1.3)                       0 (0)                               0 (0)                       1 (0.5)
  Other                                      1 (1.3)                       0 (0)                               0 (0)                       1 (0.5)
  *Missing Data*                               *0*                          *0*                                 *0*                          *0*
  **Marital status, n (%)**                                                                                                                    
  Married                                   46 (58.2)                    36 (52.2)                           44 (59.5)                    126 (56.8)
  Separated                                  2 (2.5)                      1 (1.4)                             1 (1.4)                      4 (1.8)
  Divorced                                  9 (11.4)                     17 (24.6)                            8 (10.8)                    34 (15.3)
  Widowed                                   17 (21.5)                    11 (15.9)                            9 (12.2)                    37 (16.7)
  Never Married                              5 (6.3)                      4 (5.8)                            12 (16.2)                     21 (9.5)
  *Missing Data*                               *0*                          *0*                                 *0*                          *0*
  **Level of education, n (%)**                                                                                                                
  Less than 7 yrs of school                  2 (2.5)                      1 (1.4)                             1 (1.4)                      4 (1.8)
  Grades 7 through 9                         5 (6.3)                       0 (0)                               0 (0)                       5 (2.3)
  Grades 10 through 11                       7 (8.9)                      4 (5.8)                             5 (6.8)                      16 (7.2)
  High school graduate                      13 (16.5)                    16 (23.2)                            8 (10.8)                    37 (16.7)
  1 to 4 yrs of college                     13 (16.5)                     9 (13.0)                           22 (29.7)                    44 (19.8)
  College graduate                          25 (31.6)                    21 (30.4)                           19 (25.7)                    65 (29.3)
  Professional or Graduate school           14 (17.7)                    18 (26.1)                           19 (25.7)                    51 (23.0)
  *Missing Data*                               *0*                          *0*                                 *0*                          *0*

Yrs: years, OA: osteoarthritis, kg: kilograms, m: meters, %: validity percent.

###### 

Subject's Medication at Baseline

  **Medication**                                         **Walking (W) only (n=79)**   **Walking and Behavioural (WB) (n=69)**   **Self-directed (C) (n=74)**
  ----------------------------------------------------- ----------------------------- ----------------------------------------- ------------------------------
  Oral hypoglycaemic agents                                                                                                                    
    Total                                                           2 (3)                               5 (7)                               9 (12)
    Biguanide Class                                                 2 (3)                               4 (6)                               9 (12)
    Sulfonylureas Class                                             0 (0)                               0 (0)                               2 (3)
    Thiazolidinedione                                               0 (0)                               2 (3)                               2 (3)
  Antihypertensive Agents                                                                                                                      
    Total                                                          22 (28)                             15 (22)                             15 (22)
    Calcium channel blockers                                        6(8)                                0(0)                                 7(9)
    Antiotensin-converting enzyme                                   3 (4)                              7 (10)                               7 (9)
    Angiotensin II receptor blockers                                6 (8)                               6 (9)                               3 (4)
    Beta-blocker                                                    4 (5)                               3 (4)                               4 (5)
    Alpha-blocker                                                   3 (4)                               0 (0)                               0 (0)
    Diuretic                                                        5 (6)                              8 (12)                               5 (7)
  Antiarrhythmic                                                    1 (1)                               0 (0)                               0 (0)
  Anti-anginal                                                      1 (1)                               0 (0)                               0 (0)
  Anti-platelet agent                                               1 (1)                               1 (1)                               1 (1)
  Anticoagulant                                                     0 (0)                               2 (3)                               0 (0)
  Phosphodiesterase type 5 inhibitors                               0 (0)                               1 (1)                               0 (0)
  Statins                                                          8 (10)                              12 (17)                             10 (14)
  Hormone                                                                                                                                      
    Total                                                          11 (14)                             10 (14)                             11 (15)
    Thyroid                                                         5 (6)                               5 (7)                               8 (11)
    Insulin                                                         0 (0)                               3 (4)                               1 (1)
    Corticosteroid                                                  4 (5)                               2 (3)                               3 (4)
    Progesterone                                                    1 (1)                               0 (0)                               1 (1)
    Androgen                                                        1 (1)                               0 (0)                               0 (0)
    Oestrogen                                                       1 (1)                               0 (0)                               0 (0)
  Antithyroid                                                       0 (0)                               1 (1)                                0(0)
  SERMs (Selective estrogen receptor modifiers)                     1 (1)                               0 (0)                               0 (0)
  Beta 2-adrenergic receptor agonist (bronchodilator)               2(3)                                1 (1)                               3 (4)
  NSAIDs (Non-steroid anti-inflammatory drugs)                     26 (33)                             21 (30)                             18 (24)
  COX-2 selective inhibitor                                         3 (4)                               4 (6)                               1 (1)
  NSAIDS                                                                                                                                       
  Betahistine                                                       0 (0)                               1 (1)                               0 (0)
  DMARDs (Disease modifying antirheumatic drugs)                    0 (0)                               1 (1)                               0 (0)
  Histamine antagonist                                              0 (0)                               2 (3)                               0 (0)
  Bisphosphonate                                                    6 (8)                               4 (6)                               4 (5)
  Antibiotics                                                       2 (3)                               1 (1)                               4 (5)
  Analgesics                                                        1 (1)                               1 (1)                               3 (4)
  Opiates                                                           0 (0)                               0 (0)                               2 (3)
  Hypnotic                                                          4 (5)                               3 (4)                               4 (5)
  Antidepressant                                                    7 (9)                               5 (7)                               7 (9)
  Psychostimulant                                                   0 (0)                               1 (1)                               0 (0)
  Antipsychotic                                                     0 (0)                               1 (1)                               0 (0)
  Anti-manic                                                        0 (0)                               1 (1)                               0 (0)
  Anti-convulsant                                                   1 (1)                               1 (1)                               0 (0)
  Protein pump inhibitor (PPI)                                     9 (11)                               5 (6)                               6 (8)
  Enzyme inhibitor                                                  0 (0)                               1 (1)                               2 (3)
  Muscle relaxant                                                   0 (0)                               1 (1)                               1 (1)
  Antispasmodic                                                     0 (0)                               1 (1)                               0 (0)
  Anti-cholinergic                                                  1 (1)                               1 (1)                               0 (0)
  Antineoplastic                                                    2 (3)                               1 (1)                               0 (0)
  Antimetabolite                                                    1 (1)                               1 (1)                               1 (1)
  Antifolate                                                        0 (0)                               1 (1)                               1 (1)
  Latanoprost                                                       0 (0)                               1 (1)                               0 (0)
  Viscosupplementation                                              0 (0)                               1 (1)                               0 (0)
  Xanthine                                                          1 (1)                               0 (0)                               0 (0)
  Antifungals                                                       0 (0)                               0 (0)                               1 (1)
  Antimalarial                                                      0 (0)                               1 (1)                               1 (1)
  Nitrate                                                           0 (0)                               0 (0)                               2 (3)
  Laxative                                                          0 (0)                               0 (0)                               2 (3)
  Supplements                                                      22 (28)                             22 (28)                             18 (24)
  Homeopathic Medication                                            1 (1)                               1 (1)                               1 (1)
  None                                                             11 (14)                             10 (13)                              9 (12)
  Not Specific                                                     21 (27)                             21 (27)                             20 (27)
  Missing Data                                                                                                                                 
    Total                                                           4 (5)                              8 (10)                              17 (23)
    No Evaluation\*                                                 2 (3)                               4 (5)                               7 (9)
    No File\*\*                                                     2 (3)                               4 (6)                              10 (14)

This table presents a list of medications which participants declared to be taking at baseline. Data is presented as n (%).

###### 

Summary of adherence based on attendance marked in trainers' manuals and individual walkers' logbooks

                     **Walking N Mean±SD**   **Walking & Behavioural N Mean±SD**   **Self-directed (C) N Mean±SD**   **Walking vs. Self-directed*t*-test P value**   **Walking & Behavioural Vs. Self-directed*t*-test P value**   **Walking & Behavioural Vs. Walking*t*-test P value**
  ----------------- ----------------------- ------------------------------------- --------------------------------- ----------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------
  0-3 months                  79                             69                                  73                                    \*(0.043)                                              \*(0.012)                                                   (0.514)
                          0.770±0.299                    0.802±0.290                         0.652±0.403                                                                                                                                                      
  3-6 months                  79                             69                                  73                                     (0.242)                                                (0.159)                                                    (0.774)
                          0.617±0.410                    0.636±0.390                         0.535±0.459                                                                                                                                                      
  6-9 months                  79                             69                                  73                                     (0.421)                                                (0.937)                                                    (0.363)
                          0.471±0.418                    0.534±0.425                         0.528±0.463                                                                                                                                                      
  9-12 months                 79                             69                                  73                                     (0.549)                                                (0.551)                                                    (0.989)
                          0.446±0.441                    0.445±0.433                         0.490±0.462                                                                                                                                                      
  Total Adherence             79                             69                                  73                                     (0.690)                                                (0.413)                                                    (0.619)
                          0.576±0.346                    0.604±0.342                         0.551±0.420                                                                                                                                                      

###### 

Summary of self-efficacy, measured with Stanford questionnaire on chronic disease for three study arms (continued)

                  **Baseline**   **12 months**   **18 months**                                                                        
  -------------- -------------- --------------- --------------- ------------- ------------- ------------- ------------- ------------- -------------
  Variables         Mean±SD         Mean±SD         Mean±SD        Mean±SD       Mean±SD       Mean±SD       Mean±SD       Mean±SD       Mean±SD
                                                                 W.Vs. C(P)    W.Vs. C(P)    W.Vs. W(P)    W.Vs. C(P)    W.Vs. C(P)    W.Vs. W(P)
  Coping               79             69              73             44            44            40            44            41            36
  With             1.069±794      1.126±0.775     1.013±0.946    0.864±0.771   1.239±0.730   1.192±0.835   1.064±0.952   1.388±0.856   1.342±1.127
  Symptoms                                                         (0.091)       (0.858)       (0.057)       (0.190)       (0.793)       (0.286)
  Confidence           79             69              73             44            44            39            43            41            36
  About           7.406±1.719     7.827±1.488     7.858±1.512    7.826±1.551   7.682±1.785   8.064±1.575   7.690±1.920   7.546±1.848   8.015±1.476
  Doing Things                                                     (0.433)       (0.297)       (0.060)       (0.235)       (0.422)      \*(0.041)

(Higher is better) W: Walking only group; WB: Walking and Behavioural Group; C: Self-directed group (unsupervised/self-directed); N: number of subjects in each comparative group; SD: standard deviation; vs: versus; data is presented as mean (standard deviation); p: p-value (statistical significance); \* Statistically significant.

### Supervised walking programs (WB & W groups)

The SCAWPs took place at two walking club sites in Ottawa, Ontario, Canada and one in Gatineau, Québec, Canada. Participants took part in three weekly walking sessions over a 12-month period. Every walking session began with a 10-minute warm-up, consisting of light aerobic exercises, before engaging in the 45-minute aerobic walking phase. The walking sessions ended with a 10-minute cool-down consisting of light aerobic exercises and stretching. The target intensity of the walking phase was approximately 50% to 70% of the subjects' pre-determined maximum heart rate as recommended in The Ottawa Panel guidelines \[[@B33]-[@B35]\]. The SCAWP was divided into two stages: 1) A "progressive aerobic phase" wherein the duration and heart rate intensity progressively increased over time and 2) a "maintenance aerobic phase" wherein the duration and heart rate intensity remained constant for the remainder of the walking program (Additional file [2](#S2){ref-type="supplementary-material"}). The selected dosage, frequency, intensity, and progression of the walking interventions were based on existing protocols proven effective for OA, described in several RCTs involving individuals with OA \[[@B33]-[@B35]\] (Additional file [2](#S2){ref-type="supplementary-material"}). To avoid contamination between the two walking interventions, participants in the W group were instructed to walk in the mornings, while the WB group walked in the afternoons at the main walking site.

In order to meet the prescribed target heart rate, heart rate monitors were provided to each participant prior to his/her walking session. As a safety precaution, participants who experienced prolonged pain lasting more than two hours within 24 hours after a walking session were asked to temporarily reduce their level of exercise until he/she felt comfortable enough to resume the appropriate duration, intensity and frequency of the walking program. Following randomization, the PA specialist met each subject in the walking groups to explain the SCAWP and its progression (Additional file [2](#S2){ref-type="supplementary-material"}) and was present for a minimum of three weekly scheduled sessions over one year to supervise the subjects. The PA specialist was responsible for monitoring and recording attendance, blood pressure, heart rate (during and after the walking session), time duration, and number of steps (pedometer) at each walking session. Monetary compensation was given to each participant for attending each walking session.

### Behavioural intervention (WB group)

The behavioural intervention was part of the multifaceted KT intervention (Table [1](#T1){ref-type="table"}) and was implemented using the adapted *Program for Arthritis Control through Education and Exercise* (PACEex) program \[[@B40]\]. The behavioural intervention was integrated into the PACEex program and consisted of the following components: (1) short- and long-term goal setting during PACEex classes; (2) an educational component, delivered by a trained instructor, involving consisting of instructional sessions about the benefits of PA, specifically walking; (3) monthly face-to-face counselling wherein participants received moral support/encouragement to adherence with PA. Potential barriers to program adherence were identified and self-management strategies were reviewed to overcome those barriers; (4) goal setting and telephone counselling were provided as an additional source of social support until the end of the supervised phase. As with the face-to-face counselling, barriers were identified and strategies were shared in an effort to promote the long-term maintenance of PA. In summary, the behavioural intervention consisted of twenty 2-hour group sessions discussing short-term goal setting and education of arthritis-related topics over a duration of 20 consecutive weeks. Individual long-term goal setting was discussed at the beginning of the PACEex program and was followed by monthly face-to-face meetings throughout the first 6 months of the program. The last six months of the 12-month supervised phase consisted of participants receiving counselling via telephone discussing long-term goals and barriers/facilitators to adhere to the walking program.

### The self-directed control (C group)

Participants were invited to consult an educational pamphlet on walking and OA. One introductory session was provided to the participant wherein they were provided an educational pamphlet describing the benefits of walking for OA, a pedometer to monitor PA, and a logbook to record activity level and adherence while partaking in the self-directed walking program. Participants in this group received monetary compensation for the completion his/her log books. The self-directed (C) group did not have any contact with participants in the two other groups, avoiding potential contamination.

Data collection
---------------

Participants were assessed by an independent evaluator at baseline and at each 3 month interval (months 3, 6, 9, 12) during the intervention period. Participants were then assessed at 3 and 6 months post-intervention during the follow-up period (15 and 18-months). Participants were asked to complete a collection of validated questionnaires as well as perform physical tests at each assessment.

Results
=======

Knowledge (CPG) uptake outcome measures (KT outcomes)
-----------------------------------------------------

### Adherence and behaviour change

Similar to other studies \[[@B29],[@B41],[@B42]\], participant adherence was assessed as the number of attended walking sessions divided by the number of prescribed sessions (3 sessions per week). Among the W and WB groups, the number of attended walking sessions throughout the 12-month duration was recorded by the exercise therapist on site as well as through the use of participants' completed logbooks which provided information on the amount of performed PA during the 12-month intervention period. The C group's adherence was only assessed by the completed log books. Behaviour change was based on the concept of self-efficacy and was measured using the Stanford scale. In regards to the research question, behaviour change results were only reported at 12 and 18-months.

### Analysis

The analysis was conducted on an intention-to-treat basis. Descriptive statistics including mean, standard deviation and frequencies were used to summarize the study groups at baseline. A repeated measure mixed model was used to assess the change in adherence from baseline to end of treatment (12 months) among three study groups. Behavioural change outcomes were assessed from baseline to of end treatment (12 months) and at 6-month follow-up post-intervention (18 months). The model included variables such as intervention group, study month, and an interaction term between intervention group and study month. Missing data was assumed to be missing at random (MAR) in order to include incomplete data. Pairwise differences comparing each group to one another (W vs. C, W vs. WB, WB vs. C) were assessed. The repeated measure mixed model was used to compare the change of adherence from baseline to the 18- month follow-up. Statistical analyses were performed using SAS (version 9.2, SAS Institute Inc., Cary, North Carolina), and statistical significance was defined as p\<0.05.

Results
=======

Between January 2007 and December 2008, 629 study participants were assessed for eligibility. Figure  [2](#F2){ref-type="fig"} exhibits the flow of participants from recruitment to follow-up. The most common reasons for exclusion were: 1) time commitment (26.5%); 2) first diagnosed with OA by physician or X-Ray but later contradicted by MRI test result (18.1%); 3) loss of interest (14.2%); 4) severe OA of the weight bearing joint of LE (11.8%); 5) no medical clearance after VO2 max test (5.1%); 6) unable to contact (4.9%); 7) too active (2,9%); 8) knee replacement (2.7%); 9) age related (2.5%); 10) travelling too much (1.9%); 11) living too far (1.2%). Follow-up for the last recruited participant was completed in May 2010.

![**Study flow diagram.** This figure provides a flow diagram of data collection from baseline to 18-months follow-up.](1471-2458-12-871-2){#F2}

The groups were similar in age, sex, ethnicity, OA duration and medication use (Table [2](#T2){ref-type="table"} &[3](#T3){ref-type="table"}). Two hundred and twenty two subjects were included in the study. Women made up 153 of the 222 subjects. The mean age (±S.D.) was 63.4 (±8.6) years, the mean disease duration (±S.D.) was 10.3 (±9.3) years, the highest level of completed education was "College graduate" with 65 participants (±29.3) and "Professional or graduate school" with 51 participants (±23.0). There was no statistical difference between the three comparative groups at baseline for all the demographic variables.

Blinding
--------

The effectiveness of blinding the evaluator to treatment allocation was assessed through a questionnaire where she was asked to identify which group each participant belonged to. The blinding rate of the evaluator was high (98%).

Adherence and attrition
-----------------------

From baseline to 12 months, the adherence rates were expressed as percentages of adherence among walkers who did not drop out and were reported as means (+/−standard deviation) for each time period between groups (Table [4](#T4){ref-type="table"}). Statistically significant results for short-term adherence rates favoured participants in the WB group (80.2%) compared to the self-directed (C) group (65.2%) (p\<0.012) after 3 months. For long term adherence (6 to 12 months), the WB group demonstrated superior adherence rates throughout each period compared to the other two groups, but results did not reach statistical significance. No statistical significance (p\> 0.05) was observed for the total adherence rates between WB vs. W, W vs. C, and WB vs. C.

During the 12-month intervention period, the dropout rates were 43.1% for the W group, 40.6% for the WB group and 49.3% for the self-directed (C) group. From baseline to 18 months, the dropout rates were 44.3% for the W group; 40.6% for the WB group and 52.1% for the self-directed (C) group (Figure  [2](#F2){ref-type="fig"} and Additional files [3](#S3){ref-type="supplementary-material"} &[4](#S4){ref-type="supplementary-material"}). The dropout rates were lower for the WB group at 12-months (36.2%) and 18-months (39.1%) compared to the W group (40.5% and 44.3%) and the self-directed (C) group (40.5% and 51.3%). The W and self-directed (C) groups had the highest dropout rates (40.5%) at 12 months while the self-directed (C) group had the highest at 18 months (52.1%).

Behaviour change
----------------

After the 12 month intervention phase, no differences were found between the 3 comparative groups for any of the items on the Stanford scale (Table [5](#T5){ref-type="table"}). Moreover, variables related to coping with symptoms and confidence were higher among the WB group compared to the other two groups.

At 18-months, statistically significant differences in scores between the WB and W groups revealed that the W group demonstrated an improved mean for the "confidence about doing things" variable (p=0.041). The self-directed group (C) demonstrated the highest mean "confidence about doing things" score 8.015± 1.476 (p=0.040) as it increased by 0.157 (p=0.048) when compared to baseline. The self-directed group (C) demonstrated the highest mean score 8.015± 1.476 (p=0.040).

Discussion
==========

The Impact of the multifaceted KT interventions on knowledge (CPG) uptake
-------------------------------------------------------------------------

### Adherence and attrition

The additional behavioural approach of the multifaceted KT intervention (WB group) improved adherence to the SCAWP when compared to the other two groups over a short-term period. In addition, the WB group demonstrated reduced dropout rates compared to the W and self-directed (C) groups. Over a long-term period, the three groups were equivalent in improving behaviour change while adopting the Ottawa Panel recommendations on walking \[[@B33]-[@B35]\]. Adherence rates were higher among the WB group for each 3-month period compared to the other two groups. Improved adherence rates over the short-term period can be explained by the fact the PACEex program used in the behavioural intervention lasted for 20 consecutive weeks at the beginning of the study. The PACEex program \[[@B40]\] used in this study, allowed our participants to set general goals, which may have motivated participants to adhere to the walking program. Similar to a previous study \[[@B43]\], another reason may be that participants in the W and WB group lost motivation after the supervised phase, no longer having regular professional support from the PA specialist.

The drop-out rate results are comparable to other long-term studies which have used an aerobic PA intervention with a behavioural intervention component \[[@B38],[@B44]-[@B54]\]. Higher adherence rates were demonstrated at 2 to 4 months (85% - 90%) and at 10 to 18 months (50% - 90%). An initial 6-month center-based exercise program enhanced retention over short and the long-term periods while promoting short-term adherence and energy expenditure \[[@B55]\]. The moderate exercise intervention retained more subjects, but had little influence on adherence over a long-term period \[[@B56]\]. Home-based PA programs, such as self-directed walking, can achieve improved adherence rates compared to facility-based programs over a long period \[[@B55]\].

Behaviour change
----------------

There were no statistically significant results among the three groups at 12 months. These results concur with a similar study \[[@B53]\] and are normal in the context of a KT study which implemented an already proven effective walking program \[[@B33]-[@B35]\]. However, at 18-months, there were statistically significant results which favoured the self-directed group (C). One reason explaining why participants in the self-directed group (C) had higher confidence and self-efficacy scores may be due to the fact that since these individuals were not supervised, they may have been more independent, self-controlled, self-confident, and self-motivated. Participants in this group may have also had the opportunity, over the 12-month period, to develop confidence and self-efficacy skills compared to the two supervised groups during the unsupervised follow-up phase.

The variable "confidence about doing things" decreased after 12 months for the WB group. Given the high amount of PA demonstrated by the WB group at 12 months, we were surprised with this result. On the other hand, at 18 months, statistically significant results favoured the W group compared to WB group for the variables "confidence about doing things". Again, these results about confidence were unexpected given that the WB group performed higher amounts of PA.

Exercise therapists, pedometers, logbooks and social support from walking club members (Table [1](#T1){ref-type="table"}) assisted participants who had difficulties with activity adherence and maintenance \[[@B57]\]. Regular professional contact was recognised as the significant motivational factor for adherence to the supported walking program during the RCT \[[@B43]\]. Social support has been reported to be more successful in engaging participants in PA programs compared to programs which only provided written educational material \[[@B58],[@B59]\]. The combination of using pedometers and goal-setting has been recognised as an effective KT tool for increasing PA \[[@B31],[@B60]-[@B62]\]. However, despite the short-term effectiveness of pedometers and goal-setting, the success of these tools diminished over time. Other KT strategies are recommended to facilitate sustainability \[[@B62]\].

Limitations
-----------

Barriers related to the implementation of SCAWP were identified and addressed to improve adherence for older individuals \[[@B57]\]. Acceptability (preferences, tolerance and accessibility) should be considered to promote PA adherence and to overcome associated barriers \[[@B63]\]. The most common barriers identified by participants with OA are perceptions about illness and recovery, transportation difficulties, family commitments and inconvenient timing \[[@B64]\]. Time commitment is also recognised as a significant barrier \[[@B55]\]. Additional barriers such as weather conditions including snow storms, freezing rain and humidity, a 3-month bus strike, and health problems of participants' partners may have contributed to study adherence.

Adherence is influenced by participant's preference of intervention \[[@B65]-[@B70]\]. Unfortunately, with this study being a RCT, taking participants' preference into consideration was not possible due to the randomization procedure. This being said, randomisation may have contributed to higher dropout rates. The purpose of this KT study was to implement a scientifically proven effective walking program for OA \[[@B33]-[@B35]\].

Short term research suggests that self-management interventions \[[@B16],[@B18]\], telephone counselling \[[@B22],[@B46],[@B71]-[@B73]\], peer support \[[@B13],[@B74]-[@B76]\] and PA education \[[@B18],[@B22],[@B27],[@B41],[@B77]\] are effective behavioural strategies for improving self-efficacy. The long-term multifaceted behavioural strategy used in this study did not concur with the previous studies, as participants in the self-directed group (C group) were provided information and education on the benefits of PA.

Methods of measurement for adherence for the W and WB groups were different than the self-directed (C) group. Observed attendance was recorded on site for each walking session for the W and WB groups by exercise therapists while adherence could only be measured in the self-directed group (C) using completed logbooks. The self-reporting of PA, which is commonly overstated, may have been subject to potential information bias.

Selection bias may have occurred as our study population included individuals with mild to moderate OA, with a confirmed X-ray report. In addition, some participants were retired while some were still employed. Since participants were provided monetary compensation for their participation in the study, one may argue the generalizability of the results.

Implications
------------

This KT RCT aimed to identify the best multifaceted strategy to implement a proven effective walking program for OA of the knee among older individuals. The epidemic public health problem of OA can be managed through the implementation of a proven effective walking program in existing community-based walking clubs as well as at home with minimal support. More studies are needed to improve the long-term walking adherence or knowledge uptake on SCAWP among participants with OA. Particular attention should focus on patients' characteristics and preferences.

Conclusions
===========

This study partially supported our initial hypothesis regarding the impact of a multifaceted KT intervention as the combined walking and behavioural approach had greater benefits over the comparative groups resulting in improved long-term adherence to PA only over a short period (3-months). The WB group demonstrated to be the best KT strategy for reducing dropouts compared to the W group and self-directed (C) group. All three KT strategies were equivalent over the long-term period (up to 18 months) for improving behavioural change. However, the self-directed walking program (C group) was the least expensive to implement over a long-period (18 months). This RCT was a long-term adherence study as well as a KT study which addressed questions of clinical and scientific importance aimed at improving the understanding of effective KT strategies to promote the adoption and maintenance of a community-based walking program for OA.
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